PRESS INFORMATIONHeading: 2025 annual results        Nanterre, March 11, 2026 (after trading) Net profit, Group share stable in 2025Financial statements at December 31 (1) 2024 2025Revenues 810.4 857.2Business operating profit (2) 84.1 (10.4%) 82.1 (9.6%)Operating profit 77.9 (9.6%) 75.6 (8.8%)Financial profit/loss 10.2 9.5Income tax (24.9) (23.2)Net profit 63.2 (7.8%) 61.9 (7.2%)– of which, group share 52.5 52.1Free cash flow (3) 74.6 62.2Net cash net of financial debt (4) 319.5 336.6Staff at year-end 7,087 7,208(1)        In millions of euros, 2025 financial statements approved by the Board of Directors on March 11, 2026.(2)        Before cost of bonus shares(3)        Cash flow from operational activities, plus financial profit and less net industrial investments.(4)        Excluding IFRS16...

ANNUAL RESULTS FOR 2025Consolidated turnover: €160.3M, +2.1% (at constant exchange rate: +3.0%)EBITDA (1) = €18.7M, +13.0%Net Result = €6.8M, +11.8%Dividend = €1.0 per share, +4.2% Blagnac, France, March 11th, 2026, after closing of the Stock Market. SOGECLAIR, supplier of innovative solutions with high added value for a safer and less-consuming mobility publishes its financial results for the year ended December 31, 2025. SOGECLAIR is listed on Euronext Growth in Paris. The Board of Directors, which met on March 10th, 2026, has approved the financial statements for the year ended December 31, 2025. The audit procedures on the annual accounts have been carried out.All interim management figures improved, with EBITDA at 11.7% of turnover, increasing to €18.7 million, operating income at 6.4% of turnover, up significantly to €10.2 million,...

Sogeclair: annual results for 2025 (slideshow)AttachmentSOGECLAIR – SFAF 2025 RESULTS

RAPALA VMC CORPORATION, Financial Statement Release, March 11, 2026 at 3:00 p.m. EET Rapala VMC Corporation’s Financial Statement Release 2025:Continuous improvements through successful new prodcucts & improved operations January-December (FY) in brief:Net sales were 227.5 MEUR, up 3% from previous year (220.9). With comparable exchange rates sales were 6 % higher than last year. Comparable operating profit* was 8.4 MEUR (6.2).The improved profitability was primarily driven by increased sales and controlled operating expenses. Cash flow from operations was 5.5 MEUR (23.4). Net profit for the period was -4.9 EUR (0.4). Main negative impact related to non-cash foreign currency translation loss arising from dicontinued manufacturing operations. 2026 guidance: Full year comparable operating profit* to increase from the previous...

Broad-Based Global Growth and Expanded Customer Trust Position eCommerce Retailer for Long-Term Scalable Success IRVINE, Calif., March 11, 2026 (GLOBE NEWSWIRE) — iHerb, a leading global eCommerce retailer specializing in vitamins, minerals, supplements and other health and wellness products, today announced record financial and operational performance for fiscal year 2025, highlighted by generating $2.9 billion in net sales, up 19% year-over-year while significantly increasing profitability. Sales increased in 28 of iHerb’s top 30 countries, with growth across all regions and product categories, reflecting resilient global demand and continued market share gains. The company fulfilled more than 44 million orders during the year and served 15 million active customers worldwide. More customers are increasingly choosing iHerb as their...

– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year – – YCANTH dispensed applicator units grew 99% to 51,296 in 2025 versus 25,773 units in 2024 – Company is advancing VP-315, its novel oncolytic peptide, toward a Phase 3 program for basal cell carcinoma in 2026, further analysis supports abscopal effects and tumor size reduction in untreated lesions – – First patient dosed in the first Phase 3 study of YCANTH for the treatment of common warts in December 2025, and Company expects to initiate the second Phase 3 study in the US and Japan with Torii Pharmaceutical in mid-2026 – – Company gained alignment with the European Medicines Agency supporting...

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage  Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million Remaining Performance Obligations Increased 43% to Approximately $70 Million Issuing 2026 Guidance: Expecting Revenue of $66 – $68 million (27% – 30% Growth), Operating Income of 13% – 14%, and Adjusted EBITDA of $12 – $14 Million (86% – 100% Growth) Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2026 (GLOBE NEWSWIRE) —  BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive...

Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, exclusive license to TAPI’s innovative forms of resmetirom active pharmaceutical ingredients (API) First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Positive topline results in open-label Phase 3 trial evaluating the long-term safety of denifanstat in patients with moderate to severe acne in China reported by Ascletis China’s National Medical Products Administration (NMPA) accepted Ascletis’ New Drug Application (NDA) for denifanstat for the treatment of moderate to severe acne SAN MATEO, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical...

Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today provided business updates and reported financial results for the fourth quarter and year ended December 31, 2025. Business Updates Strategic Financing On October 23, 2025, Minerva received $80.0 million in gross proceeds from a private placement, before deducting fees and other expenses. The financing included initial upfront funding of $80.0 million and up to an additional $80.0 million if all Tranche A warrants are exercised, subject to...

2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year; Net Income of $20.2 Million, up 40% Year-over-Year Company Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Double-Digit Organic Growth Generated $25.5 Million of Cash from Operations in 2025; as of December 31, 2025 had $75.5 Million of Available Cash Company Aims to Secure New Business Development and M&A Transactions to Accelerate Profitable Growth Company Adopted an Annual Cash Dividend Policy and Declares Cash Dividend of $0.25 Per Share (Totaling Approximately $14.4 Million) Conference Call and Live Webcast Today at 8:30am ETREHOVOT, Israel, and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ:...